remission induction therapy

remission induction therapy

Oncology Initial chemotherapy administered to a Pt with CA, intended to achieve remission
Mentioned in ?
References in periodicals archive ?
Although our patient showed complete remission, even after remission induction therapy, there are chances that the cancer might come back.
Prednisolone has been used as part of remission induction therapy in early RA and undifferentiated arthritis in IMPROVED study which revealed high percentage of remission rates.
Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study).
Treatment Considerations: Treatment of GPA includes remission induction therapy and remission maintenance therapy.
Remission Induction Therapy: Standard remission induction therapy for patients with severe disease consists of oral prednisolone and oral cyclophosphamide 2mg/kg/day with monitoring of CBC, renal functions.
These encouraging results led to the initiation of the Phase III study, POLO-AML-2, investigating volasertib in combination with LDAC, in patients aged 65 years and above with previously untreated AML who are ineligible for intensive remission induction therapy.
Since an early blast cell clearance by remission induction therapy is a major independent prognostic factor, the improved outcome in our patients could be related with the initial striking decrease in leukemic cells in the bone marrow and in the extramedullary site obtained with HDMP as a differentiating- and apoptosis-inducing agent.
These data suggest that for limited WG, MTX may be as good a choice as CTX as remission induction therapy.
Based on these data, NanoMed is utilizing Nanotemplate Engineering to develop its lead product which is intended to overcome multidrug resistance in remission induction therapy in elderly acute myelogenous leukemia (AML) patients," Benoit added.
The Phase 3 trial is designed as an open-label, randomized, active control, multi-center study of Xanafide in combination with cytarabine compared to daunorubicin in combination with cytarabine as initial remission induction therapy for patients with sAML.
The current standard of care for remission induction therapy results in poor treatment response rates in many AML patients, especially the elderly and those with secondary AML.
Previous multi-center studies of patients with secondary AML identified remission rates of 24-26% following remission induction therapy with the existing conventional therapy.